No Data
No Data
Executive Reshuffles: SBUX, KR, and LVS
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Falls 8% Following CFO Departure Announcement
Express News | BioCryst Pharmaceuticals Inc - CFO Anthony Doyle to Resign Effective April 9, 2025
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $18
Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its Yearly Results